{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T15:46:09Z","timestamp":1794239169119,"version":"4.9.0"},"reference-count":124,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,17]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>The skin is one of the most important organs in the body, providing integrity and acting as a barrier to exclude microbes, allergens and chemicals. However, chronic skin inflammation can result when barrier function is defective and immune responses are dysregulated or misdirected against harmless or self-antigens. During the last 15 years interleukin (IL)-17 cytokines have emerged as key players in multiple inflammatory disorders, and they appear to be especially prominent in skin inflammation. IL-17 cytokines produced by T cells and other cell types potently activate keratinocytes to promote inflammation in a feed-forward loop. Given this key pathogenic role of the IL-17 pathway in autoimmune and inflammatory disease, it has been the focus of intense efforts to target therapeutically. The inflammatory effects of IL-17 can be targeted directly by blocking the cytokine or its receptor, or indirectly by blocking cytokines upstream of IL-17-producing cells. Psoriasis has been the major success story for anti-IL-17 drugs, where they have proven more effective than in other indications. Hidradenitis suppurativa (HS) is another inflammatory skin disease which, despite carrying a higher burden than psoriasis, is poorly recognized and under-diagnosed, and current treatment options are inadequate. Recently, a key role for the IL-17 pathway in the pathogenesis of HS has emerged, prompting clinical trials with a variety of IL-17 inhibitors. In this review, we discuss the roles of IL-17A, IL-17F and IL-17C in psoriasis and HS and the strategies taken to target the IL-17 pathway therapeutically.<\/jats:p>","DOI":"10.1111\/cei.13449","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T08:50:41Z","timestamp":1588841441000},"page":"121-134","source":"Crossref","is-referenced-by-count":157,"title":["IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa"],"prefix":"10.1093","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0670-6659","authenticated-orcid":false,"given":"J M","family":"Fletcher","sequence":"first","affiliation":[{"name":"School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland"},{"name":"School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8243-1079","authenticated-orcid":false,"given":"B","family":"Moran","sequence":"additional","affiliation":[{"name":"School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0420-5252","authenticated-orcid":false,"given":"A","family":"Petrasca","sequence":"additional","affiliation":[{"name":"School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1701-1665","authenticated-orcid":false,"given":"C M","family":"Smith","sequence":"additional","affiliation":[{"name":"School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"2021121023212957900_cei13449-bib-0001","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.4049\/jimmunol.150.12.5445","article-title":"CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene","volume":"150","author":"Rouvier","year":"1993","journal-title":"J Immunol"},{"key":"2021121023212957900_cei13449-bib-0002","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.4049\/jimmunol.155.12.5483","article-title":"Human IL-17: a novel cytokine derived from T cells","volume":"155","author":"Yao","year":"1995","journal-title":"J Immunol"},{"key":"2021121023212957900_cei13449-bib-0003","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E","article-title":"Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium","volume":"42","author":"Chabaud","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2021121023212957900_cei13449-bib-0004","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3109\/08830189809043008","article-title":"Interleukin-17","volume":"16","author":"Fossiez","year":"1998","journal-title":"Int Rev Immunol"},{"key":"2021121023212957900_cei13449-bib-0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med"},{"key":"2021121023212957900_cei13449-bib-0006","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"2021121023212957900_cei13449-bib-0007","first-page":"1363","article-title":"Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders","volume":"17","author":"Balato","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"2021121023212957900_cei13449-bib-0008","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","article-title":"Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis","volume":"192","author":"Cheuk","year":"2014","journal-title":"J Immunol"},{"key":"2021121023212957900_cei13449-bib-0009","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41467-018-07911-6","article-title":"RORgammat inhibition selectively targets IL-17 producing iNKT and gammadelta-T cells enriched in spondyloarthritis patients","volume":"10","author":"Venken","year":"2019","journal-title":"Nat Commun"},{"key":"2021121023212957900_cei13449-bib-0010","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.4049\/jimmunol.1100804","article-title":"Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2 T cell subset with a potential role in psoriasis","volume":"187","author":"Laggner","year":"2011","journal-title":"J Immunol"},{"key":"2021121023212957900_cei13449-bib-0011","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","article-title":"Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation","volume":"35","author":"Cai","year":"2011","journal-title":"Immunity"},{"key":"2021121023212957900_cei13449-bib-0012","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/jid.2014.146","article-title":"Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR(+) ILC3 in lesional skin and blood of psoriasis patients","volume":"134","author":"Teunissen","year":"2014","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0013","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4049\/jimmunol.1100123","article-title":"Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis","volume":"187","author":"Lin","year":"2011","journal-title":"J Immunol"},{"key":"2021121023212957900_cei13449-bib-0014","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1189\/jlb.3HI1215-542R","article-title":"Human mast cells capture, store, and release bioactive, exogenous IL-17A","volume":"100","author":"Noordenbos","year":"2016","journal-title":"J Leukoc Biol"},{"key":"2021121023212957900_cei13449-bib-0015","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3389\/fimmu.2018.00795","article-title":"A reappraisal on the potential ability of human neutrophils to express and produce IL-17 family members in vitro: failure to reproducibly detect it","volume":"9","author":"Tamassia","year":"2018","journal-title":"Front Immunol"},{"key":"2021121023212957900_cei13449-bib-0016","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ni.2156","article-title":"IL-17C regulates the innate immune function of epithelial cells in an autocrine manner","volume":"12","author":"Ramirez-Carrozzi","year":"2011","journal-title":"Nat Immunol"},{"key":"2021121023212957900_cei13449-bib-0017","doi-asserted-by":"crossref","first-page":"25487","DOI":"10.1074\/jbc.M111.240671","article-title":"Tumor necrosis factor alpha-mediated induction of interleukin 17C in human keratinocytes is controlled by nuclear factor \u03baB","volume":"286","author":"Johansen","year":"2011","journal-title":"J Biol Chem"},{"key":"2021121023212957900_cei13449-bib-0018","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/jid.2013.313","article-title":"The pattern recognition receptor NOD2 mediates Staphylococcus aureus-induced IL-17C expression in keratinocytes","volume":"134","author":"Roth","year":"2014","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0019","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.4049\/jimmunol.1201505","article-title":"Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation","volume":"190","author":"Johnston","year":"2013","journal-title":"J Immunol"},{"key":"2021121023212957900_cei13449-bib-0020","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/imr.12558","article-title":"IL-25 in allergic inflammation","volume":"278","author":"Xu","year":"2017","journal-title":"Immunol Rev"},{"key":"2021121023212957900_cei13449-bib-0021","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.immuni.2018.03.019","article-title":"An interleukin-25-mediated autoregulatory circuit in keratinocytes plays a pivotal role in psoriatic skin inflammation","volume":"48","author":"Xu","year":"2018","journal-title":"Immunity"},{"key":"2021121023212957900_cei13449-bib-0022","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front Immunol"},{"key":"2021121023212957900_cei13449-bib-0023","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.immuni.2019.02.001","article-title":"Dysregulated lung commensal bacteria drive interleukin-17B production to promote pulmonary fibrosis through their outer membrane vesicles","volume":"50","author":"Yang","year":"2019","journal-title":"Immunity"},{"key":"2021121023212957900_cei13449-bib-0024","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.immuni.2015.03.008","article-title":"Interleukin-17B antagonizes interleukin-25-mediated mucosal inflammation","volume":"42","author":"Reynolds","year":"2015","journal-title":"Immunity"},{"key":"2021121023212957900_cei13449-bib-0025","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3389\/fimmu.2019.01172","article-title":"Interleukin-17D promotes pathogenicity during infection by suppressing CD8 T cell activity","volume":"10","author":"Lee","year":"2019","journal-title":"Front Immunol"},{"key":"2021121023212957900_cei13449-bib-0026","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1097\/CCM.0000000000004070","article-title":"Interleukin-17D aggravates sepsis by inhibiting macrophage phagocytosis","volume":"48","author":"Yan","year":"2020","journal-title":"Crit Care Med"},{"key":"2021121023212957900_cei13449-bib-0027","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1006\/cyto.1997.0240","article-title":"Molecular characterization of the human interleukin (IL)-17 receptor","volume":"9","author":"Yao","year":"1997","journal-title":"Cytokine"},{"key":"2021121023212957900_cei13449-bib-0028","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.4049\/jimmunol.181.4.2799","article-title":"The human IL-17F\/IL-17A heterodimeric cytokine signals through the IL-17RA\/IL-17RC receptor complex","volume":"181","author":"Wright","year":"2008","journal-title":"J Immunol"},{"key":"2021121023212957900_cei13449-bib-0029","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau9657","article-title":"Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation","volume":"4","author":"Su","year":"2019","journal-title":"Sci Immunol"},{"key":"2021121023212957900_cei13449-bib-0030","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.immuni.2020.02.004","article-title":"Structural analysis reveals that the cytokine IL-17F forms a homodimeric complex with receptor IL-17RC to drive IL-17RA-independent signaling","volume":"52","author":"Goepfert","year":"2020","journal-title":"Immunity"},{"key":"2021121023212957900_cei13449-bib-0031","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2021121023212957900_cei13449-bib-0032","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ni1497","article-title":"Development, cytokine profile and function of human interleukin 17-producing helper T cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat Immunol"},{"key":"2021121023212957900_cei13449-bib-0033","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"2021121023212957900_cei13449-bib-0034","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s13555-017-0187-0","article-title":"Guselkumab for the treatment of psoriasis: a review of Phase III trials","volume":"7","author":"Nakamura","year":"2017","journal-title":"Dermatol Ther"},{"key":"2021121023212957900_cei13449-bib-0035","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.immuni.2015.08.019","article-title":"Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation","volume":"43","author":"Maxwell","year":"2015","journal-title":"Immunity"},{"key":"2021121023212957900_cei13449-bib-0036","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"key":"2021121023212957900_cei13449-bib-0037","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.immuni.2008.02.019","article-title":"Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis","volume":"28","author":"Izcue","year":"2008","journal-title":"Immunity"},{"key":"2021121023212957900_cei13449-bib-0038","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"2021121023212957900_cei13449-bib-0039","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1126\/science.1200439","article-title":"Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity","volume":"332","author":"Puel","year":"2011","journal-title":"Science"},{"key":"2021121023212957900_cei13449-bib-0040","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) Project Team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0041","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jaad.2016.07.065","article-title":"Psoriasis and comorbid diseases: Implications for management","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2021121023212957900_cei13449-bib-0042","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat Commun"},{"key":"2021121023212957900_cei13449-bib-0043","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1046\/j.1523-1747.1998.00347.x","article-title":"Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes","volume":"111","author":"Teunissen","year":"1998","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0044","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/BF02832018","article-title":"The expression of interleukin-17, interferon-gamma, and macrophage inflammatory protein-3 alpha mRNA in patients with psoriasis vulgaris","volume":"24","author":"Li","year":"2004","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"2021121023212957900_cei13449-bib-0045","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells","volume":"128","author":"Lowes","year":"2008","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0046","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010641","article-title":"Resident memory T cells in human health and disease","volume":"7","author":"Clark","year":"2015","journal-title":"Sci Transl Med"},{"key":"2021121023212957900_cei13449-bib-0047","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.jid.2018.02.030","article-title":"Resident T cells in resolved psoriasis steer tissue responses that stratify clinical outcome","volume":"138","author":"Gallais Serezal","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0048","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","article-title":"Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin","volume":"160","author":"Johansen","year":"2009","journal-title":"Br J Dermatol"},{"key":"2021121023212957900_cei13449-bib-0049","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/1203475415584503","article-title":"IL-17A, IL-22, and IL-23 as markers of psoriasis activity: a cross-sectional, hospital-based study","volume":"19","author":"Fotiadou","year":"2015","journal-title":"J Cutan Med Surg"},{"key":"2021121023212957900_cei13449-bib-0050","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","article-title":"A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes","volume":"80","author":"Cargill","year":"2007","journal-title":"Am J Hum Genet"},{"key":"2021121023212957900_cei13449-bib-0051","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ng.2467","article-title":"Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity","volume":"44","author":"Tsoi","year":"2012","journal-title":"Nat Genet"},{"key":"2021121023212957900_cei13449-bib-0052","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.4049\/jimmunol.1103233","article-title":"CIKS\/Act1-mediated signaling by IL-17 cytokines in context: implications for how a CIKS gene variant may predispose to psoriasis","volume":"188","author":"Sonder","year":"2012","journal-title":"J Immunol"},{"key":"2021121023212957900_cei13449-bib-0053","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-0625.2011.01412.x","article-title":"IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion","volume":"21","author":"Gutowska-Owsiak","year":"2012","journal-title":"Exp Dermatol"},{"key":"2021121023212957900_cei13449-bib-0054","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tips.2008.11.004","article-title":"Interleukin-17 as a drug target in human disease","volume":"30","author":"Ivanov","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"2021121023212957900_cei13449-bib-0055","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br J Dermatol"},{"key":"2021121023212957900_cei13449-bib-0056","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1084\/jem.20061308","article-title":"Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides","volume":"203","author":"Liang","year":"2006","journal-title":"J Exp Med"},{"key":"2021121023212957900_cei13449-bib-0057","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0058","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis","volume":"131","author":"Carrier","year":"2011","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0059","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1038\/jid.2013.361","article-title":"IL36RN mutations in generalized pustular psoriasis: just the tip of the iceberg?","volume":"133","author":"Capon","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0060","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1208\/s12248-017-0094-4","article-title":"Ultra-sensitive measurement of IL-17A and IL-17F in psoriasis patient serum and skin","volume":"19","author":"Soderstrom","year":"2017","journal-title":"AAPS J"},{"key":"2021121023212957900_cei13449-bib-0061","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J Biol Chem"},{"key":"2021121023212957900_cei13449-bib-0062","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/jid.2008.294","article-title":"Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis","volume":"129","author":"Watanabe","year":"2009","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0063","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00403-010-1033-8","article-title":"Involvement of IL-17F via the induction of IL-6 in psoriasis","volume":"302","author":"Fujishima","year":"2010","journal-title":"Arch Dermatol Res"},{"key":"2021121023212957900_cei13449-bib-0064","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/ni.2155","article-title":"IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens","volume":"12","author":"Song","year":"2011","journal-title":"Nat Immunol"},{"key":"2021121023212957900_cei13449-bib-0065","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.jid.2016.06.009","article-title":"Keratinocyte-derived IL-17E contributes to inflammation in psoriasis","volume":"136","author":"Senra","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0066","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/00002281-200105000-00003","article-title":"Anti-tumor necrosis factor therapies","volume":"13","author":"Taylor","year":"2001","journal-title":"Curr Opin Rheumatol"},{"key":"2021121023212957900_cei13449-bib-0067","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Express Study Investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"2021121023212957900_cei13449-bib-0068","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"N Engl J Med"},{"key":"2021121023212957900_cei13449-bib-0069","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2217\/imt-2017-0063","article-title":"A review on golimumab in the treatment of psoriatic arthritis","volume":"9","author":"Urdaneta","year":"2017","journal-title":"Immunotherapy"},{"key":"2021121023212957900_cei13449-bib-0070","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/09546630410017275","article-title":"A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab","volume":"15","author":"Scheinfeld","year":"2004","journal-title":"J Dermatolog Treat"},{"key":"2021121023212957900_cei13449-bib-0071","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3389\/fimmu.2018.01668","article-title":"Psoriasis, cardiovascular events, and biologics: lights and shadows","volume":"9","author":"Caiazzo","year":"2018","journal-title":"Front Immunol"},{"key":"2021121023212957900_cei13449-bib-0072","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"key":"2021121023212957900_cei13449-bib-0073","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2013 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"2021121023212957900_cei13449-bib-0074","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER- 3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"2021121023212957900_cei13449-bib-0075","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2021121023212957900_cei13449-bib-0076","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/jdv.14387","article-title":"Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients","volume":"31","author":"Masson Regnault","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021121023212957900_cei13449-bib-0077","first-page":"155","article-title":"New plaque psoriasis approval carries suicide warning","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2021121023212957900_cei13449-bib-0078","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2017.08.024","article-title":"Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials","volume":"78","author":"Lebwohl","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2021121023212957900_cei13449-bib-0079","doi-asserted-by":"crossref","first-page":"13466","DOI":"10.1038\/ncomms13466","article-title":"IL-12 protects from psoriasiform skin inflammation","volume":"7","author":"Kulig","year":"2016","journal-title":"Nat Commun"},{"key":"2021121023212957900_cei13449-bib-0080","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"2021121023212957900_cei13449-bib-0081","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","article-title":"Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study","volume":"139","author":"Gordon","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0082","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2021121023212957900_cei13449-bib-0083","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"key":"2021121023212957900_cei13449-bib-0084","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13006","article-title":"Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: a 104-week clinical study","volume":"32","author":"Rompoti","year":"2019","journal-title":"Dermatol Ther"},{"key":"2021121023212957900_cei13449-bib-0085","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ad.2015.06.004","article-title":"An update on hidradenitis suppurativa (Part I): epidemiology, clinical aspects, and definition of disease severity","volume":"106","author":"Martorell","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"2021121023212957900_cei13449-bib-0086","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/jid.2012.255","article-title":"Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota","volume":"133","author":"Vazquez","year":"2013","journal-title":"J Investigative Dermatol"},{"key":"2021121023212957900_cei13449-bib-0087","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jaad.2008.06.020","article-title":"Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies","volume":"59","author":"Revuz","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2021121023212957900_cei13449-bib-0088","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2340\/0001555576482483","article-title":"A case\u2013control study of hidradenitis suppurativa in an STD population","volume":"76","author":"Jemec","year":"1996","journal-title":"Acta Derm Venereol"},{"key":"2021121023212957900_cei13449-bib-0089","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","article-title":"Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States","volume":"153","author":"Garg","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2021121023212957900_cei13449-bib-0090","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/bjd.14038","article-title":"Diagnostic delay in hidradenitis suppurativa is a global problem","volume":"173","author":"Saunte","year":"2015","journal-title":"Br J Dermatol"},{"key":"2021121023212957900_cei13449-bib-0091","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaad.2017.02.005","article-title":"Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis","volume":"77","author":"Garg","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2021121023212957900_cei13449-bib-0092","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.det.2015.08.002","article-title":"Prevalence, risk factors, and comorbidities of hidradenitis suppurativa","volume":"34","author":"Miller","year":"2016","journal-title":"Dermatol Clin"},{"key":"2021121023212957900_cei13449-bib-0093","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jaad.2017.07.027","article-title":"Uncovering burden disparity: a comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa","volume":"77","author":"Hamzavi","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2021121023212957900_cei13449-bib-0094","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/jmg.22.5.367","article-title":"A family study of hidradenitis suppurativa","volume":"22","author":"Fitzsimmons","year":"1985","journal-title":"J Med Genet"},{"key":"2021121023212957900_cei13449-bib-0095","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1600-0625.2009.00915.x","article-title":"Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis","volume":"19","author":"von Laffert","year":"2010","journal-title":"Exp Dermatol"},{"key":"2021121023212957900_cei13449-bib-0096","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1126\/science.1196284","article-title":"Gamma-secretase gene mutations in familial acne inversa","volume":"330","author":"Wang","year":"2010","journal-title":"Science"},{"key":"2021121023212957900_cei13449-bib-0097","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.jid.2016.04.036","article-title":"Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa","volume":"136","author":"Hotz","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0098","article-title":"Hair follicle stem cell replication stress drives IFI16\/STING-dependent inflammation in hidradenitis suppurativa [published online ahead of print, 2020 Apr 2]","author":"Orvain","year":"2020","journal-title":"J Clin Invest"},{"key":"2021121023212957900_cei13449-bib-0099","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2340\/00015555-2503","article-title":"Normal skin microbiota is altered in pre-clinical hidradenitis suppurativa","volume":"97","author":"Ring","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2021121023212957900_cei13449-bib-0100","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamadermatol.2017.0904","article-title":"The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls","volume":"153","author":"Ring","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2021121023212957900_cei13449-bib-0101","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2018.02965","article-title":"Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model","volume":"9","author":"Vossen","year":"2018","journal-title":"Front Immunol"},{"key":"2021121023212957900_cei13449-bib-0102","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjd.14214","article-title":"Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa","volume":"174","author":"Lima","year":"2016","journal-title":"Br J Dermatol"},{"key":"2021121023212957900_cei13449-bib-0103","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2133.2011.10643.x","article-title":"Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions","volume":"166","author":"van der Zee","year":"2012","journal-title":"Br J Dermatol"},{"key":"2021121023212957900_cei13449-bib-0104","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.jid.2017.05.033","article-title":"Hidradenitis suppurativa Is characterized by dysregulation of the Th17 : Treg cell axis, which is corrected by anti-TNF therapy","volume":"137","author":"Moran","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"5","key":"2021121023212957900_cei13449-bib-0105","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jid.2019.08.453","article-title":"Enrichment of plasma cells in the peripheral blood and skin of patients with hidradenitis suppurativa","volume":"140","author":"Musilova","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0106","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5908","article-title":"Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa","volume":"11","author":"Byrd","year":"2019","journal-title":"Sci Transl Med"},{"key":"2021121023212957900_cei13449-bib-0107","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/thoraxjnl-2016-209887","article-title":"Neutrophil extracellular traps induced by cigarette smoke activate plasmacytoid dendritic cells","volume":"72","author":"Qiu","year":"2017","journal-title":"Thorax"},{"key":"2021121023212957900_cei13449-bib-0108","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa","volume":"65","author":"Schlapbach","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2021121023212957900_cei13449-bib-0109","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"key":"2021121023212957900_cei13449-bib-0110","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/bjd.17854","article-title":"A new T helper 17 cytokine in hidradenitis suppurativa: antimicrobial and proinflammatory role of interleukin-26","volume":"181","author":"Scala","year":"2019","journal-title":"Br J Dermatol"},{"key":"2021121023212957900_cei13449-bib-0111","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/bjd.18556","article-title":"Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa","volume":"182","author":"Navrazhina","year":"2019","journal-title":"Br J Dermatol"},{"key":"2021121023212957900_cei13449-bib-0112","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.jid.2018.02.037","article-title":"IL-17C: a unique epithelial cytokine with potential for targeting across the spectrum of atopic dermatitis and psoriasis","volume":"138","author":"Guttman-Yassky","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0113","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis suppurativa: advances in diagnosis and treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"key":"2021121023212957900_cei13449-bib-0114","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-015-0516-5","article-title":"An update on medical treatment options for hidradenitis suppurativa","volume":"76","author":"Deckers","year":"2016","journal-title":"Drugs"},{"key":"2021121023212957900_cei13449-bib-0115","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2340\/00015555-0747","article-title":"Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors","volume":"89","author":"Haslund","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"2021121023212957900_cei13449-bib-0116","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"2021121023212957900_cei13449-bib-0117","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","article-title":"Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial","volume":"82","author":"Casseres","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2021121023212957900_cei13449-bib-0118","first-page":"5","article-title":"Novel anti-IL17 antibody (CJM112) reduces inflammation of hidradenitis suppurativa patients in a placebo-controlled trial","volume":"28","author":"Kimball Aea","year":"2019","journal-title":"Exp Dermatol"},{"key":"2021121023212957900_cei13449-bib-0119","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021121023212957900_cei13449-bib-0120","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.crohns.2014.02.002","article-title":"Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect","volume":"8","author":"Parkes","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2021121023212957900_cei13449-bib-0121","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","article-title":"The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction","volume":"139","author":"Witte-Handel","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0122","first-page":"53","article-title":"Systematic review of immunomodulatory therapies for hidradenitis suppurativa","volume":"13","author":"Lim","year":"2019","journal-title":"Biologics"},{"key":"2021121023212957900_cei13449-bib-0123","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 targeting IL-1\u03b1 for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2021121023212957900_cei13449-bib-0124","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.4049\/jimmunol.179.10.7128","article-title":"IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis","volume":"179","author":"Yamaguchi","year":"2007","journal-title":"J Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.13449","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cei.13449","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cei.13449","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/201\/2\/121\/41636055\/cei13449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/201\/2\/121\/41636055\/cei13449.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T16:15:54Z","timestamp":1696090554000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/201\/2\/121\/6403151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":124,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,6,8]]},"published-print":{"date-parts":[[2020,7,17]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.13449","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,6,8]]}}}